Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders

References

• Heiss NS, Knight SW, Vulliamy TJ et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19(1), 32–38 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402(6761), 551–555 (1999).
   PubMed Web of Science ®Google Scholar
• Vulliamy T, Marrone A, Goldman F et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413(6854), 432–435 (2001).
   PubMed Web of Science ®Google Scholar
• Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol. Dis. 34(3), 257–263 (2005).
   PubMed Web of Science ®Google Scholar
• Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 107(7), 2680–2685 (2006).
   PubMed Web of Science ®Google Scholar
• Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood 113(26), 6549–6557 (2009).
   PubMed Web of Science ®Google Scholar
• Alter BP, Baerlocher GM, Savage SA et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110(5), 1439–1447 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson BH, Kasher PR, Mayer J et al. Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus. Nat. Genet. 44(3), 338–342 (2012).
   PubMed Web of Science ®Google Scholar
• Polvi A, Linnankivi T, Kivelä T et al. Mutations in CTC1, encoding the CTS telomere maintenance complex component 1, cause cerebroretinal microangiopathy with calcifications and cysts. Am. J. Hum. Genet. 90(3), 540–549 (2012).
   PubMed Web of Science ®Google Scholar
• Tsakiri KD, Cronkhite JT, Kuan PJ et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl Acad. Sci. USA 104(18), 7552–7557 (2007).
   PubMed Web of Science ®Google Scholar
• Armanios MY, Chen JJ, Cogan JD et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356(13), 1317–1326 (2007).
   PubMed Web of Science ®Google Scholar
• Calado RT, Regal JA, Kleiner DE et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS ONE 4(11), e7926 (2009).
   PubMed Web of Science ®Google Scholar
• Meyne J, Ratliff RL, Moyzis RK. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc. Natl Acad. Sci. USA 86(18), 7049–7053 (1989).
   PubMed Web of Science ®Google Scholar
• de Lange T, Shiue L, Myers RM et al. Structure and variability of human chromosome ends. Mol. Cell. Biol. 10(2), 518–527 (1990).
   PubMed Web of Science ®Google Scholar
• Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 11(21), 2801–2809 (1997).
   PubMed Web of Science ®Google Scholar
• Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 41(1), 181–190 (1973).
   PubMed Web of Science ®Google Scholar
• Watson JD. Origin of concatemeric T7 DNA. Nature New Biol. 239(94), 197–201 (1972).
   PubMedGoogle Scholar
• Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
   PubMed Web of Science ®Google Scholar
• Lundblad V, Szostak JW. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57(4), 633–643 (1989).
   PubMed Web of Science ®Google Scholar
• Zou Y, Sfeir A, Gryaznov SM, Shay JW, Wright WE. Does a sentinel or a subset of short telomeres determine replicative senescence? Mol. Biol. Cell 15(8), 3709–3718 (2004).
   PubMed Web of Science ®Google Scholar
• Liti G, Louis EJ. NEJ1 prevents NHEJ-dependent telomere fusions in yeast without telomerase. Mol. Cell 11(5), 1373–1378 (2003).
   PubMed Web of Science ®Google Scholar
• Mieczkowski PA, Mieczkowska JO, Dominska M, Petes TD. Genetic regulation of telomere-telomere fusions in the yeast Saccharomyces cerevisae. Proc. Natl Acad. Sci. USA 100(19), 10854–10859 (2003).
   PubMed Web of Science ®Google Scholar
• McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics 26(2), 234–282 (1941).
   PubMedGoogle Scholar
• Hanahan D. Benefits of bad telomeres. Nature 406(6796), 573–574 (2000).
   PubMed Web of Science ®Google Scholar
• Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev. 12(8), 1073–1085 (1998).
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 579(4), 859–862 (2005).
   PubMed Web of Science ®Google Scholar
• Hamma T, Ferré-D’Amaré AR. The box H/ACA ribonucleoprotein complex: interplay of RNA and protein structures in post-transcriptional RNA modification. J. Biol. Chem. 285(2), 805–809 (2010).
   PubMed Web of Science ®Google Scholar
• Trahan C, Martel C, Dragon F. Effects of dyskeratosis congenita mutations in dyskerin, NHP2 and NOP10 on assembly of H/ACA pre-RNPs. Hum. Mol. Genet. 19(5), 825–836 (2010).
   PubMed Web of Science ®Google Scholar
• Venteicher AS, Abreu EB, Meng Z et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 323(5914), 644–648 (2009).
   PubMed Web of Science ®Google Scholar
• Grozdanov PN, Roy S, Kittur N, Meier UT. SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs. RNA 15(6), 1188–1197 (2009).
   PubMed Web of Science ®Google Scholar
• Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 132(6), 945–957 (2008).
   PubMed Web of Science ®Google Scholar
• Fatica A, Dlakic M, Tollervey D. Naf1 p is a box H/ACA snoRNP assembly factor. RNA 8(12), 1502–1514 (2002).
   PubMed Web of Science ®Google Scholar
• Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58(18), 4168–4172 (1998).
   PubMed Web of Science ®Google Scholar
• Härle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc. Natl Acad. Sci. USA 93(13), 6476–6481 (1996).
   PubMed Web of Science ®Google Scholar
• Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155(8), 3711–3715 (1995).
   PubMed Web of Science ®Google Scholar
• Chiu CP, Dragowska W, Kim NW et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14(2), 239–248 (1996).
   PubMed Web of Science ®Google Scholar
• Armanios M. Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet. 10, 45–61 (2009).
   PubMed Web of Science ®Google Scholar
• Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere biology disorders. Genet. Med. 12(12), 753–764 (2010).
   PubMed Web of Science ®Google Scholar
• Nelson ND, Bertuch AA. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat. Res. 730(1–2), 43–51 (2012).
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Calado RT, Ly H et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N. Engl. J. Med. 352(14), 1413–1424 (2005).
   PubMed Web of Science ®Google Scholar
• Aalbers AM, Kajigaya S, van den Heuvel-Eibrink MM, van der Velden VH, Calado RT, Young NS. Human telomere disease due to disruption of the CCAAT box of the TERC promoter. Blood 119(13), 3060–3063 (2012).
   PubMed Web of Science ®Google Scholar
• Zhong F, Savage SA, Shkreli M et al. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev. 25(1), 11–16 (2011).
   PubMed Web of Science ®Google Scholar
• Canudas S, Houghtaling BR, Bhanot M et al. A role for heterochromatin protein 1g at human telomeres. Genes Dev. 25(17), 1807–1819 (2011).
   PubMed Web of Science ®Google Scholar
• Savage SA. Connecting complex disorders through biology. Nat. Genet. 44(3), 238–240 (2012).
   PubMed Web of Science ®Google Scholar
• Keller RB, Gagne KE, Usmani GN et al. CTC1 mutations in a patient with dyskeratosis congenita. Pediatr. Blood Cancer 59(2), 311–314 (2012).
   PubMed Web of Science ®Google Scholar
• Walne AJ, Bhagat T, Kirwan M et al. Mutations in the telomere capping complex in bone marrow failure and related syndromes. Haematologica 98(3), 334–338 (2013).
   PubMed Web of Science ®Google Scholar
• Ballew BJ, Yeager M, Jacobs K et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Hum. Genet. 132(4), 473–480 (2013).
   PubMed Web of Science ®Google Scholar
• Uringa EJ, Lisaingo K, Pickett HA et al. RTEL1 contributes to DNA replication and repair and telomere maintenance. Mol. Biol. Cell 23(14), 2782–2792 (2012).
   PubMed Web of Science ®Google Scholar
• Vannier JB, Pavicic-Kaltenbrunner V, Petalcorin MI, Ding H, Boulton SJ. RTEL1 dismantles T loops and counteracts telomeric G4-DNA to maintain telomere integrity. Cell 149(4), 795–806 (2012).
   PubMed Web of Science ®Google Scholar
• Walne AJ, Vulliamy T, Kirwan M, Plagnol V, Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am. J. Hum. Genet. 92(3), 448–453 (2013).
   PubMed Web of Science ®Google Scholar
• Touzot F, Callebaut I, Soulier J et al. Function of Apollo (SNM1B) at telomere highlighted by a splice variant identified in a patient with Hoyeraal–Hreidarsson syndrome. Proc. Natl Acad. Sci. USA 107(22), 10097–10102 (2010).
   PubMed Web of Science ®Google Scholar
• Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. Mutations in C16orf57 and normal-length telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndrome. Hum. Mol. Genet. 19(22), 4453–4461 (2010).
   PubMed Web of Science ®Google Scholar
• Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am. J. Hum. Genet. 82(2), 501–509 (2008).
   PubMed Web of Science ®Google Scholar
• Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat. Genet. 36(5), 447–449 (2004).
   PubMed Web of Science ®Google Scholar
• Armanios M, Chen JL, Chang YP et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc. Natl Acad. Sci. USA 102(44), 15960–15964 (2005).
   PubMed Web of Science ®Google Scholar
• Goldman F, Bouarich R, Kulkarni S et al. The effect of TERC haploinsufficiency on the inheritance of telomere length. Proc. Natl Acad. Sci. USA 102(47), 17119–17124 (2005).
   PubMed Web of Science ®Google Scholar
• Jongmans MC, Verwiel ET, Heijdra Y et al. Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita. Am. J. Hum. Genet. 90(3), 426–433 (2012).
   PubMed Web of Science ®Google Scholar
• Sorrow JM Jr, Hitch JM. Dyskeratosis congenita. First report of its occurrence in a female and a review of the literature. Arch. Dermatol. 88, 340–347 (1963).
   PubMedGoogle Scholar
• Vulliamy TJ, Kirwan MJ, Beswick R et al. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations. PLoS ONE 6(9), e24383 (2011).
   PubMed Web of Science ®Google Scholar
• Atkinson JC, Harvey KE, Domingo DL et al. Oral and dental phenotype of dyskeratosis congenita. Oral Dis. 14(5), 419–427 (2008).
   PubMed Web of Science ®Google Scholar
• Tsilou ET, Giri N, Weinstein S, Mueller C, Savage SA, Alter BP. Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita. Ophthalmology 117(3), 615–622 (2010).
   PubMed Web of Science ®Google Scholar
• Rackley S, Pao M, Seratti GF et al. Neuropsychiatric conditions among patients with dyskeratosis congenita: a link with telomere biology? Psychosomatics 53(3), 230–235 (2012).
   PubMed Web of Science ®Google Scholar
• Gadalla SM, Cawthon R, Giri N, Alter BP, Savage SA. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany. NY) 2(11), 867–874 (2010).
   PubMedGoogle Scholar
• Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 97(3), 353–359 (2012).
   PubMed Web of Science ®Google Scholar
• Lin KW, Yan J. The telomere length dynamic and methods of its assessment. J. Cell. Mol. Med. 9(4), 977–989 (2005).
   PubMed Web of Science ®Google Scholar
• Baird DM. New developments in telomere length analysis. Exp. Gerontol. 40(5), 363–368 (2005).
   PubMed Web of Science ®Google Scholar
• Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 112(9), 3594–3600 (2008).
   PubMed Web of Science ®Google Scholar
• Hoyeraal HM, Lamvik J, Moe PJ. Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Paediatr. Scand. 59(2), 185–191 (1970).
   PubMed Web of Science ®Google Scholar
• Hreidarsson S, Kristjansson K, Johannesson G, Johannsson JH. A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Paediatr. Scand. 77(5), 773–775 (1988).
   PubMed Web of Science ®Google Scholar
• Knight SW, Heiss NS, Vulliamy TJ et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal–Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br. J. Haematol. 107(2), 335–339 (1999).
   PubMed Web of Science ®Google Scholar
• Revesz T, Fletcher S, al-Gazali LI, DeBuse P. Bilateral retinopathy, aplastic anaemia, and central nervous system abnormalities: a new syndrome? J. Med. Genet. 29(9), 673–675 (1992).
   PubMed Web of Science ®Google Scholar
• Mason JO 3rd, Yunker JJ, Nixon PA et al. Proliferative retinopathy as a complication of aplastic anemia and dyskeratosis congenita. Retinal Cases & Brief Reports 3, 259–262 (2009).
   PubMedGoogle Scholar
• Alder JK, Chen JJ, Lancaster L et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13051–13056 (2008).
   PubMed Web of Science ®Google Scholar
• Savage SA, Alter BP. Dyskeratosis congenita. Hematol. Oncol. Clin. North Am. 23(2), 215–231 (2009).
   PubMed Web of Science ®Google Scholar
• Savage SA, Dokal I, Armanios M et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr. Blood Cancer 53(3), 520–523 (2009).
   PubMedGoogle Scholar
• Eiler ME, Frohnmayer D, Frohnmayer L, Larsen K, Owen J (Eds). Fanconi Anemia: Guidelines for Diagnosis and Management (3rd Edition). Fanconi Anemia Research Fund, Inc., OR, USA (2008).
   Google Scholar
• Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 24(3), 101–122 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Rahawan MM, Giri N, Alter BP. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int. J. Hematol. 83(3), 275–276 (2006).
   PubMed Web of Science ®Google Scholar
• Berthou C, Devergie A, D’Agay MF et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br. J. Haematol. 79(2), 335–336 (1991).
   PubMed Web of Science ®Google Scholar
• De La Fuente J, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatric Transplantation 11(6), 584–594 (2007).
   PubMed Web of Science ®Google Scholar
• Yabe M, Yabe H, Hattori K et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant. 19(4), 389–392 (1997).
   PubMed Web of Science ®Google Scholar
• Dror Y, Freedman MH, Leaker M et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant. 31(10), 847–850 (2003).
   PubMed Web of Science ®Google Scholar
• Brazzola P, Duval M, Fournet JC et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant. 36(12), 1103–1105; author reply 1105 (2005).
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Ostronoff M, Calixto R et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. Biol. Blood Marrow Transplant. 13(3), 366–368 (2007).
   PubMed Web of Science ®Google Scholar
• Vuong LG, Hemmati PG, Neuburger S et al. Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita. Acta Haematol. 124(4), 200–203 (2010).
   PubMed Web of Science ®Google Scholar
• Dietz AC, Orchard PJ, Baker KS et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 46(1), 98–104 (2011).
   PubMed Web of Science ®Google Scholar
• Nishio N, Takahashi Y, Ohashi H et al. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita. Pediatr. Transplant. 15(2), 161–166 (2011).
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Yamaguchi H, Wiestner A et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 362(9396), 1628–1630 (2003).
   PubMed Web of Science ®Google Scholar
• Denny CC, Wilfond BS, Peters JA, Giri N, Alter BP. All in the family: disclosure of ‘unwanted’ information to an adolescent to benefit a relative. Am. J. Med. Genet. A 146A(21), 2719–2724 (2008).
   PubMed Web of Science ®Google Scholar
• Khincha P, Wentzensen I, Giri N, Alter BP, Savage SA. Response to androgen therapy and side effects in patients with dyskeratosis congenita. Presented at: American Society of Hematology Annual Meeting Atlanta, GA, USA, 6–11 December 2012.
   Google Scholar
• Giri N, Pitel PA, Green D, Alter BP. Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br. J. Haematol. 138(6), 815–817 (2007).
   PubMed Web of Science ®Google Scholar
• Giri N, Lee R, Faro A et al. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: case report and systematic literature review. BMC Blood Disord. 11, 3 (2011).
   PubMedGoogle Scholar
• Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br. J. Haematol. 103(4), 990–996 (1998).
   PubMed Web of Science ®Google Scholar
• Vulliamy T, Dokal I. Dyskeratosis congenita. Semin. Hematol. 43(3), 157–166 (2006).
   PubMed Web of Science ®Google Scholar